Women accounted for approximately 73% of total prevalent Alzheimer’s cases in 2023. Credit: Antonio Marca / Shutterstock.

Estimates by data analytics company GlobalData suggest that the total prevalent cases of Alzheimer’s disease (according to the DSM-IV criteria) will increase at an annual growth rate (AGR) of 4.08% in the eight major markets (8MM) between 2023 and 2033.

This will constitute an increase from 15.99 million to 22.51 million patients in the US, France, Germany, Italy, Spain, the UK, Japan and China.

Smarter leaders trust GlobalData

Report-cover

Reports Alzheimer’s Disease Epidemiology Analysis and Forecast to 2033

Buy the report

GlobalData is the parent company of Pharmaceutical Technology.

Forecasts suggest that, of the 8MM, China will have the highest number of total prevalent cases of Alzheimer’s by DSM-IV criteria, with 10.4 million cases expected in 2033. In contrast, Spain is expected to have the lowest number at 0.62 million in the same year.

8MM: Total prevalent cases of AD by DSM-IV criteria, both sexes, ≥65 years, 2023-2033

Considering the expected epidemiological distribution of the forecast Alzheimer’s cases, GlobalData associate project manager Antara Bhattacharya noted: “In 2023, women were more affected than men, accounting for approximately 73% of the total prevalent cases.”

Further analysis demonstrated that adults aged 75 years and over accounted for almost 79% of the total prevalent cases of Alzheimer’s by DSM-IV criteria in the 8MM in 2023. By comparison, adults aged 65 to 74 accounted for approximately 21% of reported cases.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Of the 15.99 million cases, approximately 55% of total prevalent cases were mild, whilst 16% were severe.

Considering pharmaceutical priorities for the treatment of Alzheimer’s disease, Bhattacharya commented: “Mortality remains a significant concern for individuals living with Alzheimer’s disease and their families. Efforts to prevent or delay the disease are expected to have a profound impact on long-term outcomes, as the value of treatment will largely depend on a therapy’s effectiveness in reducing morbidity and extending life expectancy.

“Therefore, extensive research can improve our understanding of the crucial relationship between Alzheimer’s disease and mortality. Moreover, the treatment for Alzheimer’s disease requires a multifaceted approach that integrates medical interventions, lifestyle modifications, ongoing support, along with clinical trials, and follow-up care.”